Clinical Trial

Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease

Recruiting
View on ClinicalTrials.gov →
Summary
This is a study to measure liver recovery in patients with recent alcohol-associated liver injury by assessing liver function and physiology using HepQuant DuO. The HepQuant DuO Test is a blood-based test that involves a drink of a natural compound, cholate, and 2 blood samples at 20 and 60 minutes. The study team is collecting clinical and laboratory data to better monitor and treat patients who have been affected by alcohol-associated liver disease. The study has 4 visits at an outpatient clinic at 1, 3, 6, and 12 months. At each of these visits, participants will undergo a HepQuant DuO test and other standard tests. In addition, the study team will ask about a participant's alcohol use, symptoms, and quality of life.
Trial Details
NCT Number NCT07060547
Lead Sponsor HepQuant, LLC
Collaborators: Leland Stanford Junior University
Conditions Alcoholic Hepatitis, Alcohol-related Liver Disease
Enrollment 40 participants
Start Date 2025-06-10
Primary Completion 2031-12 (estimated)
Study Completion 2032-03 (estimated)
Updated on ClinicalTrials.gov 2025-07-11